Recent Achievements About Targeted Alpha Therapy-Based Targeting Vectors and Chelating Agents Publisher Pubmed



Farzipour S¹ ; Shaghaghi Z^{2, 3} ; Abbasi S⁴ ; Albooyeh H⁵ ; Alvandi M⁶
Source: Anti-Cancer Agents in Medicinal Chemistry Published:2022

Abstract

One of the most rapidly growing options in the management of cancer therapy is Targeted Alpha Therapy (TAT) through which lethal α-emitting radionuclides conjugated to tumor-targeting vectors selectively deliver high amount of radiation to cancer cells.225Ac,212Bi,211At,213Bi, and223Ra have been investigated by plenty of clinical trials and preclinical researches for the treatment of smaller tumor burdens, micro-metastatic disease, and post-surgery resid-ual disease. In order to send maximum radiation to tumor cells while minimizing toxicity in normal cells, a high affini-ty of targeting vectors to cancer tissue is essential. Besides that, the stable and specific complex between chelating agent and α-emitters was found as a crucial parameter. The present review was planned to highlight recent achievements about TAT-based targeting vectors and chelating agents and provide further insight for future researches. © 2022 Bentham Science Publishers.